Title: Kirk Willis Johnson. Excitatory amino acid receptor antagonist and 5-ht1f agonist combination: a method for the treatment of neurological disorders. WO 2002053139A2.
186544-26-3
1253186-56-9 | GSK-7975A | AA01EOGL | MFCD28411366
130466-38-5 | Vatinoxan hydrochloride | AA01EOLY | MFCD08056257
1496552-28-3 | Sofosbuvir impurity C | AA01EOPV | MFCD28386805
1451369-32-6 | 3-(1-naphthalenylcarbonyl)-1H-indole-1-propanoicacid | AA01EP06
31554-45-7 | 2-(3,5-dinitro-2-thienyl)-cyclohexanone | AA01EPB3 | MFCD00667456
89339-17-3 | (1R,2R,3S,5S)-3-[(2-hydroxybenzoyl)oxy]-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylicacid,methylester | AA01EPHM
192070-02-3 | (3aS,4S,6aR)-hexahydro-N-[6-[[(1S,2R,3E)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl]amino]-6-oxohexyl]-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide | AA01EPO0 | MFCD19705498
80651-65-6 | (5α,17β)-androst-2-eno[2,3-d]isoxazol-17-ol | AA01EPUL
70803-56-4 | N-decyl-4-O-β-D-galactopyranosyl-D-gluconamide | AA01EQ3P
131587-28-5 | N-(3-fluorophenyl)-1-(phenylmethyl)-4-piperidinamine | AA01EQA3 | MFCD01308815
